Endometriosis Is Undervalued: A Call to Action

Area of Science:

• Reproductive health
• Chronic pain management
• Medical research funding

Background:

• Endometriosis affects at least 11% of women worldwide, causing chronic inflammatory pain.
• Diagnosis is often delayed due to the need for surgical confirmation, increasing symptom severity and costs.
• Current treatments like pain management and birth control are often ineffective and do not address infertility or cancer risks.

Purpose of the Study:

• To highlight the significant global burden of endometriosis.
• To emphasize the critical need for increased research funding for endometriosis.
• To advocate for advancements in diagnostic and treatment methodologies.

Main Methods:

• Literature review and analysis of disease prevalence and economic impact.
• Examination of current diagnostic and treatment limitations.
• Assessment of research funding allocation relative to disease burden.

Main Results:

• Endometriosis impacts over 190 million women globally, with significant societal and economic costs.
• Research funding, such as from the NIH, is disproportionately low (0.038% of the 2022 health budget).
• Diagnostic delays and ineffective treatments exacerbate patient suffering and healthcare expenses.

Conclusions:

• Endometriosis research requires greater funding and attention commensurate with its prevalence and impact.
• Advancements in diagnostics (e.g., biomarkers) and treatments (e.g., nanomedicine, microbiome alterations) are needed.
• Increased investment can lead to improved patient outcomes, timely diagnosis, and effective management.